Compare Colgate-Palmolive Company (CL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs TG Therapeutics Inc — how do they compare? Colgate-Palmolive Company trades at $92.43 (market cap $73.59B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Colgate-Palmolive Company is far larger — about 9.6× TG Therapeutics Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CL | TGTX | |
|---|---|---|
Market Cap | $73.59B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $59.06 |
52-Week Low | $74.98 | $26.94 |
Enterprise Value | $80.07B | $7.84B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $92.54, down 0.65% on the day, with neutral technical signals and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% revenue growth and margin expansion. Recent news highlights director share sales and mixed regional performance, particularly weakness in North America despite global strength.
CL offers stable dividend returns and consistent earnings but faces valuation concerns with a P/E of 36.34 and competitive pressures in key markets. Analyst consensus targets $99.10 with 42% buy ratings, suggesting moderate upside potential balanced against premium valuation and domestic market challenges.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
